FY2025 EPS Estimates for Affimed Raised by Cantor Fitzgerald

Affimed (NASDAQ:AFMD) – Equities researchers at Cantor Fitzgerald raised their FY2025 EPS estimates for shares of Affimed in a research report issued to clients and investors on Thursday, May 15th. Cantor Fitzgerald analyst L. Watsek now anticipates that the biopharmaceutical company will post earnings of ($0.86) per share for the year, up from their previous estimate of ($2.07). Cantor Fitzgerald currently has a “Hold” rating on the stock. The consensus estimate for Affimed’s current full-year earnings is ($4.19) per share.

Several other equities research analysts also recently commented on AFMD. Wells Fargo & Company reiterated an “equal weight” rating and set a $0.10 price objective (down from $11.00) on shares of Affimed in a research note on Tuesday, May 13th. StockNews.com started coverage on Affimed in a research note on Monday. They issued a “sell” rating for the company. Leerink Partners reiterated a “market perform” rating and set a $0.39 price target (down previously from $5.00) on shares of Affimed in a research note on Tuesday, May 13th. HC Wainwright lowered Affimed from a “buy” rating to a “neutral” rating in a report on Wednesday, May 14th. Finally, Leerink Partnrs cut Affimed from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $7.90.

Affimed Trading Down 34.9%

NASDAQ:AFMD opened at $0.18 on Monday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93. Affimed has a twelve month low of $0.07 and a twelve month high of $8.95. The company’s 50 day moving average is $0.70 and its two-hundred day moving average is $1.36.

Hedge Funds Weigh In On Affimed

A hedge fund recently bought a new stake in Affimed stock. Northern Trust Corp bought a new position in shares of Affimed (NASDAQ:AFMD) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 183,118 shares of the biopharmaceutical company’s stock, valued at approximately $218,000. Northern Trust Corp owned 1.14% of Affimed as of its most recent SEC filing. 30.82% of the stock is currently owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.